NCT01174004 - A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis | Biotech Hunter

Enrollment

199

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Parkinson's Disease Psychosis

Interventions

DRUG

pimavanserin tartrate

pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks

DRUG

placebo

placebo, tablet, once daily by mouth for 6 weeks

Trial Locations (63)

10016

New York

11725

Commack

12208

Albany

12401

Kingston

15601

Greensburg

21287

Baltimore

22311

Alexandria

23456

Virginia Beach

24018

Roanoke

27607

Raleigh

27705

Durham

28144

Salisbury

30033

Decatur

30912

Augusta

32174

Ormond Beach

32405

Panama City

32806

Orlando

33486

Boca Raton

33713

St. Petersburg

33980

Port Charlotte

34102

Naples

34205

Bradenton

37027

Brentwood

39232

Flowood

40202

Louisville

43210

Columbus

43614

Toledo

44195

Cleveland

45219

Cincinnati

48066

Roseville

48377

Novi

49684

Traverse City

53233

Milwaukee

59802

Missoula

60007

Elk Grove Village

60026

Glenview

63110

St Louis

66160

Kansas City

77030

Houston

84108

Salt Lake City

85004

Phoenix

85013

Phoenix

85234

Gilbert

85724

Tucson

90631

La Habra

90746

Carson

91105

Pasadena

91335

Reseda

92037

La Jolla

92354

Loma Linda

92697

Irvine

92708

Fountain Valley

92835

Fullerton

93003

Ventura

93030

Oxnard

93720

Fresno

94085

Sunnyvale

06810

Danbury

04074

Scarborough

02215

Boston

08755

Toms River

02906

Providence

K1G 4G3

Ottawa